Amneal’s shares fell 2.0% to $18.08 on August 6, the same day its latest filing showed a business selling more and keeping more of each dollar. Revenue rose 9.9% to $796.2 million in the three months ended June 30, while gross profit grew 16.9% to $334.5 million.
The bottom line made the move look even larger: net income jumped 157.2% to $57.7 million. But the cash picture was less cooperative. Inventory rose 11.3%, faster than revenue, and free-cash-flow margin declined 9.6 percentage points. Amneal added profit, but the filing leaves open how much of that improvement is traveling through the business as cash.
Management points first to Affordable Medicines, where product mix and volume helped lift the segment’s gross margin. The company also says those gains had to absorb higher plant and freight costs, along with inventory obsolescence.
"Affordable Medicines gross profit as a percentage of net revenue increased to 42.3% for the three months ended June 30, 2026 from 41.7% in the prior year period, primarily due to favorable product mix from recently launched products and higher sales volumes, partially offset by increased plant and freight costs and inventory obsolescence."
10-Q, August 6, 2026
That is a useful distinction. The margin improvement was not simply a lower-cost quarter. New products and higher volumes helped, while the physical business still carried more expense in freight, plants, and inventory obsolescence.
The other part of the filing is smaller, but harder to ignore. AvKARE revenue fell 3.7% to $157.0 million, and its gross profit dropped 21.0%. Amneal attributed the sales decline mainly to lower-margin distribution sales, partly offset by new products in its government-label channel.
"AvKARE net revenue for the three months ended June 30, 2026 decreased 3.7% as compared to the prior year period, primarily driven by a reduction in our low margin distribution sales, partially offset by expansion in our government label channel from new product introductions."
10-Q, August 6, 2026
So the consolidated numbers contain a reshuffle: the company sold more overall, but one line shrank as low-margin distribution revenue receded. That can support the gross-margin percentage, even before considering the newer products. The filing does not quantify how much of the total margin expansion came from that mix shift.
The balance sheet adds another measurement problem. Cash increased 78.4% to $127.6 million, but capital spending consumed a larger share of revenue and capex rose 8.0%. Inventory reached $678.0 million. A larger cash balance and weaker free-cash-flow margin are both true, and they describe different parts of the same three-month period.
There was also relief below operating income. The company disclosed lower interest expense from reduced rates on variable-rate debt, alongside a $3.5 million refinancing loss in the first quarter and unfavorable foreign-currency movements. Research and development fell 18.7% to $39.0 million for the three months ended June 30, 2026. Separately, management attributed the six-month Specialty R&D decline to lower in-licensing and upfront milestone payments.
That backdrop matters because Amneal has spent the past few annual periods expanding margins, with 2025 revenue at $3.0 billion and operating margin at 13.1%. The latest filing extends that operating improvement, but it also puts inventory, investment, and research spending back into the frame. Growth is visible in the income statement; cash conversion is the unresolved companion metric.
Amneal’s next quarterly report will need to answer one factual question: whether inventory growth and free-cash-flow margin move back toward the revenue trend after this period’s margin expansion.